Cell No. : Cell Name
RCB3687 : MKN-7
update : 2024/06/01
|
| Comment | Human cell line derived from stomach cancer (gastric cancer; highly differentiated tubular adenocarcinoma). TKG0228 (Deposited from Tohoku Univ.). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Fukuda, Hiroshi
|
| Originator |
Hojo, H.
|
| Year of deposit |
2011
|
| Original cell |
TKG0228
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Male
|
| Age at sampling |
39 years
|
| Tissue |
stomach
|
| Disease name |
Highly differentiated tubular adenocarcinoma
|
| Classification |
cancer
|
| History |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0228）
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_1417
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
|
Culture information
|
Passage ratio |
|
1 : 3-4 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Animal PCR |
|
OK
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
5
|
| User's Publication |
5
|
| Reference |
|
4399
Homma N, Tamura G, Honda T, Matsumoto Y, Nishizuka S, Kawata S, Motoyama T.
Spreading of methylation within RUNX3 CpG island in gastric cancer.
Cancer Sci
2006
97(1):51-6
PubMed ID: 16367921
DOI: 10.1111/j.1349-7006.2005.00133.x
|
|
4501
Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T.
Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines.
Clin Cancer Res
2004
10(7):2447-51
PubMed ID: 15073123
DOI: 10.1158/1078-0432.ccr-03-0107
|
|
5050
Koyama K, Akiyama K, Kawahara H, Egashira A, Murakami H.
Alloimmunization with cultured human stomach cancer cell lines and the establishment of human-human hybridomas producing monoclonal antibodies.
Jpn J Cancer Res
1990
81(10):967-70
PubMed ID: 2121682
DOI: 10.1111/j.1349-7006.1990.tb03332.x
|
|
5075
Nakatani H, Tahara E, Yoshida T, Sakamoto H, Suzuki T, Watanabe H, Sekiguchi M, Kaneko Y, Sakurai M, Terada M, et al.
Detection of amplified DNA sequences in gastric cancers by a DNA renaturation method in gel.
Jpn J Cancer Res
1986
77(9):849-53
PubMed ID: 3095279
|
|
1861
Motoyama T, Watanabe H.
Carcinoembryonic antigen production in human gastric cancer cell lines in vitro and in nude mice.
Gan
1983
74(5):679-86
PubMed ID: 6642141
|
| User's Publication |
|
21415
Fukuoka S, Koga Y, Yamauchi M, Koganemaru S, Yasunaga M, Shitara K, Doi T, Yoshino T, Kuronita T, Elenbaas B, Wahra P, Zhang H, Crowley L, Jenkins MH, Clark A, Kojima T.
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab.
Sci Rep
2023
13(1):16017
PubMed ID: 37749105
DOI: 10.1038/s41598-023-40612-9
|
|
20887
Wang Y, Chen H, Liu W, Yan H, Zhang Y, Cheung AHK, Zhang J, Chen B, Liang L, Zhou Z, Wong CC, Wu WKK, Chan MWY, Cheng ASL, Ma BBY, Yu J, Lo KW, To KF, Kang W.
MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target.
Theranostics
2022
12(15):6509-6526
PubMed ID: 36185598
DOI: 10.7150/thno.75431
|
|
20907
Sera T, Sakuma T, Maruo K, Tsujio G, Yamamoto Y, Sugimoto A, Kushiyama S, Togano S, Kuroda K, Kasashima H, Ohira M, Maeda K.
Candidate Oncogenes, ARHGAP4, NOS3, and OR51B5, for the Development of Scirrhous-type Gastric Cancer.
Anticancer Res
2022
42(11):5195-5203
PubMed ID: 36288877
DOI: 10.21873/anticanres.16026
|
|
20203
Kast F, Schwill M, Stüber JC, Pfundstein S, Nagy-Davidescu G, Rodríguez JMM, Seehusen F, Richter CP, Honegger A, Hartmann KP, Weber TG, Kroener F, Ernst P, Piehler J, Plückthun A.
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action.
Nat Commun
2021
12(1):3790
PubMed ID: 34145240
DOI: 10.1038/s41467-021-23948-6
|
|
11505
Kageyama-Yahara N, Yamamichi N, Takahashi Y, Takeuchi C, Matsumoto Y, Sakaguchi Y, Koike K.
Tandem repeats of the 5' flanking region of human MUC5AC have a role as a novel enhancer in MUC5AC gene expression.
Biochem Biophys Rep
2019
18:100632
PubMed ID: 30993217
DOI: 10.1016/j.bbrep.2019.100632
|
Back
Top
CELL BANK Website
